AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Clinical trial NCT02694822 · COMPLETED

Trial details

NCT number: NCT02694822
Sponsor: Agenus Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Cancers Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies

Start date: 2016-04-01
Primary completion: 2022-03-30
Enrollment: 89

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.